Pricing Log in Create free account
Saturday 17 October 2026 Export CRL’s income statement to Excel — free account

Charles River Laboratories International, Inc.

CRL Healthcare Diagnostics & Research

Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

299.77 6.47 −2.11%
Market cap
$14.6B
P/E
0.0×
Fwd P/E
29.6×
Dividend yield
—
F-score
5/9
Altman Z
2.40
Beneish M
−3.11
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Charles River Laboratories International, Inc. (CRL) P/B ratio

Alert me on P/B ratio

As of 16 October 2026, Charles River Laboratories International, Inc. (CRL) trades at a P/B ratio of 5.1×. Over the past ten years it has ranged from 1.6× (April 2025) to 9.9× (September 2021); the current reading is higher than 75% of that period. That is above the Diagnostics & Research industry median of 3.1× and above the Healthcare sector median of 2.3×.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2025 3.1× 14.01%
FY2024 2.7× (17.87%)
FY2023 3.3× (10.51%)
FY2022 3.7× (50.12%)
FY2021 7.5× 27.69%
FY2020 5.8× 28.60%
FY2019 4.5× 10.54%
FY2018 4.1× (18.03%)
FY2017 5.0× 16.98%
FY2016 4.3× (15.39%)

Quarterly newest first

Period P/B ratio Change
Jun 2026 3.8× 33.53%
Mar 2026 2.9× (8.11%)
Dec 2025 3.1× 38.14%
Sep 2025 2.3× 1.72%
42 more quarters

Against its own ten years

Low 1.6× High 9.9×
Ten-year median 4.6×
Current reading's percentile 76

P/B ratio against peers

Company P/B ratio
GH Guardant Health, Inc. compare n/m
ICLR ICON PLC compare 1.4×
RVTY Revvity Inc. compare 2.4×
QGEN QIAGEN N.V. compare 2.8×
LH Labcorp Holdings Inc. compare 3.0×
DGX Quest Diagnostics Incorporated compare 3.3×
CRL Charles River Laboratories International, Inc. 5.1×
TWST Twist Bioscience Corporation compare 18.6×
MEDP Medpace Holdings, Inc. compare 40.2×
Diagnostics & Research industry median 3.1×
Healthcare sector median 2.3×
Market median 1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on CRL